dexamethasone injection
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
2512
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
March 26, 2026
Multi-Patient Analysis of Steroid-Induced Hyperglycemia in Diabetic Patients Using Continuous Glucose Monitoring.
(PubMed, J Pain Res)
- "Dexamethasone displayed a reproducible excursion phase, methylprednisolone a delayed pattern, and triamcinolone inconsistent variability. These findings highlight the utility of CGM for identifying temporal SIH features, with the first 48 to 72 hours yielding clinically reliable monitoring window."
Journal • Diabetes • Metabolic Disorders • Pain
March 26, 2026
Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss
(clinicaltrials.gov)
- P1/2 | N=9 | Not yet recruiting | Sponsor: The Affiliated Hospital of Qingdao University | N=18 ➔ 9
Enrollment change • Otorhinolaryngology
March 20, 2026
TUMOUR LYSIS SYNDROME IN ACUTE LEUKEMIA: THE ROLE OF EARLY RENAL REPLACEMENT THERAPY
(ISN-WCN 2026)
- "She received IV dexamethasone 4 mg and IV rasburicase 3 mg while on oxygenation support for respiratory distress...She was also started on allopurinol 300 mg daily along with aggressive hydration.Results Despite optimal medical therapy, her potassium level rose to 7.1 mmol/L with persistent TLS features...CVVHDF provides effective and stable correction of refractory electrolyte disturbances while maintaining hemodynamic stability. Multidisciplinary collaboration among oncology, nephrology, and critical care teams is essential to achieve optimal patient outcomes."
Acute Kidney Injury • Acute Lymphocytic Leukemia • CNS Disorders • Endocrine Disorders • Epilepsy • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Lymphoma • Metabolic Disorders • Nephrology • Oncology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • T Acute Lymphoblastic Leukemia
March 25, 2026
Cohort Validation of the Endophthalmitis Vitrectomy Study for Generalized Etiologies.
(PubMed, Clin Ophthalmol)
- "Systemic antimicrobials and dexamethasone injections were not associated with improved outcomes...While overall outcomes were similar across groups, patients with LP or worse may benefit from primary PPV. EVS principles may apply broadly across endophthalmitis etiologies."
Journal • Ocular Infections • Ocular Inflammation • Ophthalmology
March 25, 2026
Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
(PubMed, Int J Urol)
- "Corticosteroid premedication reduces skin toxicities during EV monotherapy, but its impact on survival remains uncertain and requires validation in larger studies."
Journal • Retrospective data • Oncology • Solid Tumor • Urothelial Cancer
March 25, 2026
A Prospective, Randomized Comparative Study of Intravenous and Perineural Dexamethasone as an Adjuvant to Levobupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block for Adult Patients Undergoing Elective Upper Limb Surgery.
(PubMed, Cureus)
- "Group A received 19 mL of 0.5% levobupivacaine with 1 mL of normal saline perineurally and 4 mg (1 mL) of intravenous dexamethasone. It also provides superior postoperative analgesia without increasing adverse effects. It is recommended as the preferred route for dexamethasone administration in upper limb surgeries."
Clinical • Journal • Anesthesia • Pain
March 25, 2026
Variations in corticosteroids used for asthma exacerbations in the pediatric emergency department: A PECARN Registry Study.
(PubMed, J Allergy Clin Immunol Pract)
- "Use of enteral dexamethasone in the management of asthma exacerbations has increased over time, and the type of corticosteroid administered varied by sociodemographic and clinical characteristics. Future studies should explore the comparative effectiveness of different corticosteroid regimens on clinical outcomes."
Journal • Asthma • Immunology • Obesity • Pediatrics • Pulmonary Disease • Respiratory Diseases
March 19, 2026
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1/2 | N=62 | Not yet recruiting | Sponsor: Natalie Callander
New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • TP53
March 20, 2026
The Effect of Intravenous Dexamethasone on the Duration of Peripheral Nerve Blocks in Orthopedic Surgical Adult Patients: A Systematic Review Using SWiM.
(PubMed, Orthop Nurs)
- "By extending the analgesic effects of peripheral nerve blocks, dexamethasone is a valuable addition to Enhanced Recovery After Surgery protocols, playing a key role in addressing the opioid epidemic."
Journal • Review • Anesthesia • Musculoskeletal Pain • Orthopedics • Pain
March 20, 2026
The Effect of Intravenous Dexamethasone on the Duration of Peripheral Nerve Blocks in Orthopedic Surgical Adult Patients: A Systematic Review Using SWiM.
(PubMed, Orthop Nurs)
- No abstract available
Journal • Orthopedics
March 20, 2026
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
(clinicaltrials.gov)
- P4 | N=200 | Not yet recruiting | Sponsor: Shanghai 6th People's Hospital
New P4 trial • Chemotherapy-Induced Nausea and Vomiting
March 14, 2026
Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial Carcinoma.
(PubMed, Cancers (Basel))
- "All patients received routine intravenous dexamethasone premedication before enfortumab vedotin administration. In this real-world multicenter cohort, first-line EVP with routine dexamethasone premedication was feasible, with manageable toxicity and encouraging early clinical activity, including in patients with comorbidities commonly encountered in routine clinical practice. Longer follow-up and prospective comparative studies are warranted to clarify long-term outcomes and the impact of dexamethasone on efficacy and toxicity."
Journal • Real-world evidence • Oncology • Solid Tumor • Urothelial Cancer
March 19, 2026
LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
(clinicaltrials.gov)
- P2 | N=80 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2027 ➔ Nov 2033 | Trial primary completion date: Mar 2027 ➔ Feb 2031
Trial completion date • Trial primary completion date • B Cell Lymphoma • Chronic Myelomonocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD4 • DNMT3A • IDH1 • IDH2 • SF3B1 • SRSF2 • TET2 • U2AF1 • ZRSR2
March 17, 2026
Herpes Simplex Encephalitis Mimicking a Stroke With Favorable Response to Adjuvant Corticosteroids
(SCCM 2026)
- "Despite the effectiveness of intravenous Acyclovir, a subset of patients may deteriorate due to intense cerebral inflammation, leading to cerebral edema...Antibiotics were discontinued, and intravenous dexamethasone and hypertonic saline were initiated to manage cerebral edema...The initial misdiagnosis of ischemic stroke delayed the initiation of antiviral therapy and the development of cerebral edema. The subsequent use of corticosteroids and hypertonic saline therapy was associated with rapid clinical improvement, suggesting a beneficial role in managing HSVE-related inflammation and edema."
Clinical • Cardiovascular • CNS Disorders • Cognitive Disorders • Herpes Simplex • Inflammation • Ischemic stroke • Thrombosis
March 17, 2026
A Study of Daratumumab
(clinicaltrials.gov)
- P3 | N=500 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Jan 2026 ➔ Jan 2029
Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
March 17, 2026
The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery
(clinicaltrials.gov)
- P4 | N=60 | Completed | Sponsor: Poznan University of Medical Sciences | Recruiting ➔ Completed
Trial completion • Inflammation • Pain • Pediatrics
March 17, 2026
Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults
(clinicaltrials.gov)
- P=N/A | N=120 | Recruiting | Sponsor: Poznan University of Medical Sciences | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology
March 17, 2026
Secondary Hemophagocytic Lymphohistiocytosis in an Older Adult With Persistent Fever: A Case Report
(SCCM 2026)
- "Patient was started on IV dexamethasone 20 mg/day, with rapid clinical improvement: defervescense, mental status improvement, vasopressor wean, and successful extubation...Persistent fever may be the earliest or only sign. Given the high mortality, early recognition and prompt treatment are critical."
Case report • Clinical • Atrial Fibrillation • Candidiasis • Chronic Lymphocytic Leukemia • Chronic Obstructive Pulmonary Disease • Diabetes • Endocrine Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Leukemia • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock • Thrombocytopenia • IL2 • IL2RA • ISG20 • PRF1 • UNC13D
March 17, 2026
EMAT: Elimination of Minimal Residual Disease After Transplant
(clinicaltrials.gov)
- P2 | N=30 | Active, not recruiting | Sponsor: Medical College of Wisconsin | Recruiting ➔ Active, not recruiting
Enrollment closed • Minimal residual disease • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation
March 13, 2026
I-SPY_COVID: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
(clinicaltrials.gov)
- P2 | N=1500 | Active, not recruiting | Sponsor: QuantumLeap Healthcare Collaborative | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease
March 17, 2026
Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery
(clinicaltrials.gov)
- P=N/A | N=150 | Not yet recruiting | Sponsor: Poznan University of Medical Sciences
Biomarker • New trial • Pediatrics
March 17, 2026
PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults
(clinicaltrials.gov)
- P=N/A | N=120 | Recruiting | Sponsor: Poznan University of Medical Sciences | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology
March 16, 2026
Efficacy and safety of perioperative intravenous dexamethasone in type 2 diabetes mellitus patients undergoing total hip arthroplasty: a prospective randomized controlled trial.
(PubMed, J Orthop Surg Res)
- "Perioperative Dexa administration improves early recovery outcomes in patients with T2DM undergoing THA without compromising short-term safety, although it may cause transient hyperglycemia. However, the relatively small sample size, limited follow-up period, and lack of systematic evaluation of potential complications highlight the need for larger, longer-term studies to further strengthen these observations."
Journal • Diabetes • Metabolic Disorders • Orthopedics • Pain • Type 2 Diabetes Mellitus • CRP
March 12, 2026
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
(clinicaltrials.gov)
- P1/2 | N=162 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)
New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
March 14, 2026
Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery
(clinicaltrials.gov)
- P=N/A | N=135 | Not yet recruiting | Sponsor: Ankara City Hospital Bilkent
New trial
1 to 25
Of
2512
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101